# Navan, Inc.: financial statements, quarterly

NAVN · Nasdaq · CIK 1639723 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/navn.md) · [Financials](/companies/navn/financials.md) · [Filings](/companies/navn/filings.md) · [Insiders](/companies/navn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/navn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-04-30) | period not labelled (2024-07-31) | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [151](/filings/0001639723-25-000017.md) | [132 d](/filings/0001628280-26-023250.md) | [157](/filings/0001628280-26-042552.md) | [172](/filings/0001628280-26-061416.md) | [195](/filings/0001639723-25-000017.md) | [178 d](/filings/0001628280-26-023250.md) | [220](/filings/0001628280-26-042552.md) | [233](/filings/0001628280-26-061416.md) |
| Cost of revenue | $m | not reported | not reported | [44.5](/filings/0001639723-25-000017.md) | [42.7 d](/filings/0001628280-26-023250.md) | [45.7](/filings/0001628280-26-042552.md) | [46.9](/filings/0001628280-26-061416.md) | [57.1](/filings/0001639723-25-000017.md) | [52.1 d](/filings/0001628280-26-023250.md) | [57.2](/filings/0001628280-26-042552.md) | [60.3](/filings/0001628280-26-061416.md) |
| Gross profit | $m | not reported | not reported | [107](/filings/0001639723-25-000017.md) | [89.2 d](/filings/0001628280-26-023250.md) | [112](/filings/0001628280-26-042552.md) | [125](/filings/0001628280-26-061416.md) | [138](/filings/0001639723-25-000017.md) | [126 d](/filings/0001628280-26-023250.md) | [163](/filings/0001628280-26-042552.md) | [172](/filings/0001628280-26-061416.md) |
| Research and development | $m | not reported | not reported | [33.0](/filings/0001639723-25-000017.md) | [31.6 d](/filings/0001628280-26-023250.md) | [31.4](/filings/0001628280-26-042552.md) | [33.4](/filings/0001628280-26-061416.md) | [51.2](/filings/0001639723-25-000017.md) | [35.3 d](/filings/0001628280-26-023250.md) | [39.4](/filings/0001628280-26-042552.md) | [47.2](/filings/0001628280-26-061416.md) |
| Operating income | $m | not reported | not reported | [(19.5)](/filings/0001639723-25-000017.md) | [(32.8) d](/filings/0001628280-26-023250.md) | [(15.9)](/filings/0001628280-26-042552.md) | [(12.3)](/filings/0001628280-26-061416.md) | [(79.2)](/filings/0001639723-25-000017.md) | [(89.5) d](/filings/0001628280-26-023250.md) | [(18.1)](/filings/0001628280-26-042552.md) | [(25.6)](/filings/0001628280-26-061416.md) |
| Interest expense | $m | not reported | not reported | [19.7](/filings/0001639723-25-000017.md) | [18.5 d](/filings/0001628280-26-023250.md) | [16.3](/filings/0001628280-26-042552.md) | [15.6](/filings/0001628280-26-061416.md) | [15.5](/filings/0001639723-25-000017.md) | [3.8 d](/filings/0001628280-26-023250.md) | [2.8](/filings/0001628280-26-042552.md) | [2.9](/filings/0001628280-26-061416.md) |
| Income tax | $m | not reported | not reported | [5.2](/filings/0001639723-25-000017.md) | [0.1 d](/filings/0001628280-26-023250.md) | [4.5](/filings/0001628280-26-042552.md) | [3.6](/filings/0001628280-26-061416.md) | [3.5](/filings/0001639723-25-000017.md) | [(9.4) d](/filings/0001628280-26-023250.md) | [0.8](/filings/0001628280-26-042552.md) | [2.8](/filings/0001628280-26-061416.md) |
| Net income | $m | [(49.6)](/filings/0001639723-25-000017.md) | [(42.9)](/filings/0001639723-25-000017.md) | [(41.9)](/filings/0001639723-25-000017.md) | [(46.7) d](/filings/0001628280-26-023250.md) | [(61.3)](/filings/0001628280-26-061416.md) | [(38.6)](/filings/0001628280-26-061416.md) | [(225)](/filings/0001639723-25-000017.md) | [(72.8) d](/filings/0001628280-26-023250.md) | [(20.5)](/filings/0001628280-26-061416.md) | [(29.1)](/filings/0001628280-26-061416.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.92)](/filings/0001639723-25-000017.md) | not reported | [(1.33)](/filings/0001628280-26-042552.md) | [(0.83)](/filings/0001628280-26-061416.md) | [(4.58)](/filings/0001639723-25-000017.md) | not reported | [(0.08)](/filings/0001628280-26-042552.md) | [(0.11)](/filings/0001628280-26-061416.md) |
| Basic EPS | $ per share | not reported | not reported | [(0.92)](/filings/0001639723-25-000017.md) | not reported | [(1.33)](/filings/0001628280-26-042552.md) | [(0.83)](/filings/0001628280-26-061416.md) | [(4.58)](/filings/0001639723-25-000017.md) | not reported | [(0.08)](/filings/0001628280-26-042552.md) | [(0.11)](/filings/0001628280-26-061416.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-01-31) | period not labelled (2024-01-31) | period not labelled (2024-04-30) | period not labelled (2024-07-31) | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [166](/filings/0001628280-26-023250.md) | not reported | not reported | not reported | [158](/filings/0001628280-26-023250.md) | not reported | not reported | [809](/filings/0001639723-25-000017.md) | [584](/filings/0001628280-26-061416.md) | [518](/filings/0001628280-26-042552.md) | [653](/filings/0001628280-26-061416.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [689](/filings/0001628280-26-023250.md) | not reported | not reported | [1,378](/filings/0001639723-25-000017.md) | [1,307](/filings/0001628280-26-061416.md) | [1,315](/filings/0001628280-26-042552.md) | [1,405](/filings/0001628280-26-061416.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [1,084](/filings/0001628280-26-023250.md) | not reported | not reported | [1,793](/filings/0001639723-25-000017.md) | [1,709](/filings/0001628280-26-061416.md) | [1,714](/filings/0001628280-26-042552.md) | [1,811](/filings/0001628280-26-061416.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [446](/filings/0001628280-26-023250.md) | not reported | not reported | [307](/filings/0001639723-25-000017.md) | [321](/filings/0001628280-26-061416.md) | [305](/filings/0001628280-26-042552.md) | [321](/filings/0001628280-26-061416.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [970](/filings/0001628280-26-023250.md) | not reported | not reported | [574](/filings/0001639723-25-000017.md) | [501](/filings/0001628280-26-061416.md) | [478](/filings/0001628280-26-042552.md) | [495](/filings/0001628280-26-061416.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [618](/filings/0001639723-25-000017.md) | [618](/filings/0001628280-26-023250.md) | not reported | not reported | [207](/filings/0001639723-25-000017.md) | [125](/filings/0001628280-26-042552.md) | [124](/filings/0001628280-26-042552.md) | not reported |
| Shareholders' equity | $m | [(841)](/filings/0001628280-26-023250.md) | [(1,082)](/filings/0001628280-26-023250.md) | [(1,116)](/filings/0001639723-25-000017.md) | [(1,133)](/filings/0001639723-25-000017.md) | [(1,145)](/filings/0001639723-25-000017.md) | [(1,187)](/filings/0001628280-26-061416.md) | [(1,191)](/filings/0001628280-26-061416.md) | [(1,208)](/filings/0001628280-26-061416.md) | [1,219](/filings/0001639723-25-000017.md) | [1,208](/filings/0001628280-26-061416.md) | [1,237](/filings/0001628280-26-061416.md) | [1,316](/filings/0001628280-26-061416.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.9) d](/filings/0001628280-26-023250.md) | [4.6](/filings/0001628280-26-042552.md) | [0.2 d](/filings/0001628280-26-061416.md) | [(6.1) d](/filings/0001639723-25-000017.md) | [35.0 d](/filings/0001628280-26-023250.md) | [(6.8)](/filings/0001628280-26-042552.md) | [25.2 d](/filings/0001628280-26-061416.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001628280-26-023250.md) | [0.1](/filings/0001628280-26-042552.md) | [0.1 d](/filings/0001628280-26-061416.md) | [0.4 d](/filings/0001639723-25-000017.md) | [0.3 d](/filings/0001628280-26-023250.md) | [0.1](/filings/0001628280-26-042552.md) | [0.9 d](/filings/0001628280-26-061416.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-10-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.3](/filings/0001639723-25-000017.md) | [46.1](/filings/0001628280-26-042552.md) | [46.5](/filings/0001628280-26-061416.md) | [49.3](/filings/0001639723-25-000017.md) | [250](/filings/0001628280-26-042552.md) | [256](/filings/0001628280-26-061416.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.
